neuromyelitis optica spectrum disorders | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

41,450 results for “neuromyelitis optica spectrum disorders”

Trials

View all 35548 →

Not yet recruiting

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

50 participants · First posted Jun 6, 2023

Not yet recruiting

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

24 participants · First posted Nov 7, 2023

Not yet recruiting

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

80 participants · First posted Oct 5, 2023

Drugs

View all 390 →

AIM Biological (neuromyelitis optica/parkinson's disease)

Autism Spectrum Disorders(Aelis Farma)

Satralizumab(Enspryng)

Conditions: Neuromyelitis Optica Spectrum Disorders

Rx

Organizations

View all 120 →

SPECTRUM PHARMACEUTICALS, INC.

United States

SPECTRUM HEALTH HOSPITALS

United States

Spectrum Health System

United States

News

View all 5392 →

Bio-Thera's BAT4406F Shows Promise in Neuromyelitis Optica Spectrum Disorders

New NMOSD Treatment Recommended for PBS Inclusion

EMA Recommends Amgen's Uplizna for Rare Autoimmune Disease IgG4-RD

Page 1 of 4145